205 related articles for article (PubMed ID: 16120550)
21. Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of Cancer.
Wagener DJ; van Oosterom AT; Mulder JH; Somers R; Mouridsen HT; Cortes Funes H; Thomas D; Sylvester R
Cancer Treat Rep; 1986 May; 70(5):615-8. PubMed ID: 3458532
[TBL] [Abstract][Full Text] [Related]
22. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
23. [A pharmacokinetic study on high-dose methotrexate administration--the effects of volume changes of parenteral solutions on the elimination rate].
Yoshioka S; Tsukamoto T; Nakano M; Oka S; Nakano M; Norimatsu H
Gan To Kagaku Ryoho; 1994 Jan; 21(1):97-102. PubMed ID: 8291921
[TBL] [Abstract][Full Text] [Related]
24. Methotrexate levels and outcome in osteosarcoma.
Zelcer S; Kellick M; Wexler LH; Shi W; Sankaran M; Lo S; Healey J; Huvos AG; Meyers PA; Gorlick R
Pediatr Blood Cancer; 2005 Jun; 44(7):638-42. PubMed ID: 15704189
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate pharmacokinetics and prognosis in osteosarcoma.
Graf N; Winkler K; Betlemovic M; Fuchs N; Bode U
J Clin Oncol; 1994 Jul; 12(7):1443-51. PubMed ID: 8021736
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacokinetics of methotrexate and therapeutic drug monitoring in children with osteosarcoma. Computer simulation using a pharmacokinetic model].
Piekarczyk A; Zimak J; Taljański W
Med Wieku Rozwoj; 2000; 4(2 Suppl 2):27-33. PubMed ID: 11178326
[TBL] [Abstract][Full Text] [Related]
27. Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas.
Delepine N; Delepine G; Jasmin C; Desbois JC; Cornille H; Mathé G
Biomed Pharmacother; 1988; 42(4):257-62. PubMed ID: 3191203
[TBL] [Abstract][Full Text] [Related]
28. [Severe renal impairment of methotrexate elimination after high dose therapy].
Lawrenz-Wolf B; Wolfrom C; Frickel C; Fengler R; Wehinger H; Henze G
Klin Padiatr; 1994; 206(4):319-26. PubMed ID: 7967432
[TBL] [Abstract][Full Text] [Related]
29. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
Gerber DE; Grossman SA; Batchelor T; Ye X
Cancer Chemother Pharmacol; 2007 May; 59(6):817-23. PubMed ID: 16972068
[TBL] [Abstract][Full Text] [Related]
30. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution.
Zhang W; Zhang Q; Tian X; Zhao H; Lu W; Zhen J; Niu X
Chin Med J (Engl); 2015 Jan; 128(1):111-8. PubMed ID: 25563323
[TBL] [Abstract][Full Text] [Related]
32. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy.
Min Y; Qiang F; Peng L; Zhu Z
Biopharm Drug Dispos; 2009 Nov; 30(8):437-47. PubMed ID: 19746402
[TBL] [Abstract][Full Text] [Related]
33. [Monitoring high dose methotrexate therapy (HD MTX) in children with osteosarcoma and computer simulation using a pharmacokinetic model].
Taljański W; Zimak J; Piekarczyk A
Med Wieku Rozwoj; 1999; 3(3):343-52. PubMed ID: 10910661
[TBL] [Abstract][Full Text] [Related]
34. Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue.
Jürgens H; Ebell W; Bachmann R; Kupke I; Richter O; Andräs A; Göbel U
Pediatr Pharmacol (New York); 1983; 3(3-4):157-65. PubMed ID: 6610851
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
Bacci G; Longhi A; Forni C; Fabbri N; Briccoli A; Barbieri E; Mercuri M; Balladelli A; Ferrari S; Picci P
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):505-11. PubMed ID: 17118571
[TBL] [Abstract][Full Text] [Related]
36. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
37. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia.
Plard C; Bressolle F; Fakhoury M; Zhang D; Yacouben K; Rieutord A; Jacqz-Aigrain E
Cancer Chemother Pharmacol; 2007 Sep; 60(4):609-20. PubMed ID: 17195068
[TBL] [Abstract][Full Text] [Related]
38. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
39. [Clinical observations on the use of high-dose methotrexate treatment in osteogenic sarcoma (author's transl)].
Kotz R; Leber H; Ramach W; Arbes H; Wolf A
Wien Klin Wochenschr; 1977 Jul; 89(14):474-9. PubMed ID: 70889
[TBL] [Abstract][Full Text] [Related]
40. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature.
Delepine N; Delepine G; Bacci G; Rosen G; Desbois JC
Cancer; 1996 Nov; 78(10):2127-35. PubMed ID: 8918406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]